Movement Alert｜PegBio Co Ltd Rises 8.37% in Regular Trading, Extending Gains on GLP-1 Drug Commercialization Momentum

Market Focus

May 20

On May 20, PegBio Co Ltd (02565.HK) rose 8.37% in regular trading, trading at HK$17.56/share with trading volume of HK$77.81 million, extending a multi-day rally following a surge of over 100% on May 18.

The sustained upward momentum is driven by the company's strategic commercialization partnership with Tengrui Pharmaceutical for Paidakang (维培那肽注射液/PB-119), a long-acting GLP-1 receptor agonist approved in November last year. Under the agreement announced in March, Tengrui Pharmaceutical secured exclusive mainland China commercialization rights, committing approximately HK$140 million in upfront payments and targeting cumulative sales exceeding RMB 10 billion. Additionally, on May 12, Fangzhou Jiankei and Tengrui signed a strategic cooperation to launch Paidakang on its internet hospital platform as a nationwide online debut, further catalyzing investor enthusiasm.

PegBio is a China-based biopharmaceutical company focused on innovative therapies for chronic and metabolic diseases, with a pipeline spanning type 2 diabetes, obesity, and NASH.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1191904835"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191904835\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1191904835?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 09:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191904835","market":"hk","top_or_hot":-1,"title":"Movement Alert｜PegBio Co Ltd Rises 8.37% in Regular Trading, Extending Gains on GLP-1 Drug Commercialization Momentum","media":"Market Focus","content":"<p><p>On May 20, PegBio Co Ltd (02565.HK) rose 8.37% in regular trading, trading at HK$17.56/share with trading volume of HK$77.81 million, extending a multi-day rally following a surge of over 100% on May 18.</p><p>The sustained upward momentum is driven by the company's strategic commercialization partnership with Tengrui Pharmaceutical for Paidakang (维培那肽注射液/PB-119), a long-acting GLP-1 receptor agonist approved in November last year. Under the agreement announced in March, Tengrui Pharmaceutical secured exclusive mainland China commercialization rights, committing approximately HK$140 million in upfront payments and targeting cumulative sales exceeding RMB 10 billion. Additionally, on May 12, Fangzhou Jiankei and Tengrui signed a strategic cooperation to launch Paidakang on its internet hospital platform as a nationwide online debut, further catalyzing investor enthusiasm.</p><p>PegBio is a China-based biopharmaceutical company focused on innovative therapies for chronic and metabolic diseases, with a pipeline spanning type 2 diabetes, obesity, and NASH.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PegBio Co Ltd Rises 8.37% in Regular Trading, Extending Gains on GLP-1 Drug Commercialization Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PegBio Co Ltd Rises 8.37% in Regular Trading, Extending Gains on GLP-1 Drug Commercialization Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-20 09:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 20, PegBio Co Ltd (02565.HK) rose 8.37% in regular trading, trading at HK$17.56/share with trading volume of HK$77.81 million, extending a multi-day rally following a surge of over 100% on May 18.</p><p>The sustained upward momentum is driven by the company's strategic commercialization partnership with Tengrui Pharmaceutical for Paidakang (维培那肽注射液/PB-119), a long-acting GLP-1 receptor agonist approved in November last year. Under the agreement announced in March, Tengrui Pharmaceutical secured exclusive mainland China commercialization rights, committing approximately HK$140 million in upfront payments and targeting cumulative sales exceeding RMB 10 billion. Additionally, on May 12, Fangzhou Jiankei and Tengrui signed a strategic cooperation to launch Paidakang on its internet hospital platform as a nationwide online debut, further catalyzing investor enthusiasm.</p><p>PegBio is a China-based biopharmaceutical company focused on innovative therapies for chronic and metabolic diseases, with a pipeline spanning type 2 diabetes, obesity, and NASH.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1191904835","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191904835","pubTimestamp":1779241961,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 20, PegBio Co Ltd (02565.HK) rose 8.37% in regular trading, trading at HK$17.56/share with trading volume of HK$77.81 million, extending a multi-day rally following a surge of over 100% on May...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"动态警报|PegBio Co Ltd常规交易上涨8.37%，延续GLP-1药物商业化势头的涨幅","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"On May 20, PegBio Co Ltd (02565.HK) rose 8.37% in regular trading, trading at HK$17.56/share with trading volume of HK$77.81 million, extending a multi-day rally following a surge of over 100% on May 18.The sustained upward momentum is driven by the company's strategic commercialization partnership with Tengrui Pharmaceutical for Paidakang (维培那肽注射液/PB-119), a long-acting GLP-1 receptor agonist approved in November last year. Under the agreement announced in March, Tengrui Pharmaceutical secured exclusive mainland China commercialization rights, committing approximately HK$140 million in upfront payments and targeting cumulative sales exceeding RMB 10 billion. Additionally, on May 12, Fangzhou Jiankei and Tengrui signed a strategic cooperation to launch Paidakang on its internet hospital platform as a nationwide online debut, further catalyzing investor enthusiasm.PegBio is a China-based biopharmaceutical company focused on innovative therapies for chronic and metabolic diseases, with a pipeline spanning type 2 diabetes, obesity, and NASH.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}